Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)

Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the Eur...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research reports 2023-01, Vol.19, p.100360, Article 100360
Main Authors: Okikiolu, Jumoke, Woodley, Claire, Cadman-Davies, Llywelyn, O'Sullivan, Jennifer, Radia, Deepti, Garcia, Natalia Curto, Harrington, Patrick, Kordasti, Shahram, Asirvatham, Susan, Sriskandarajah, Priya, Saunders, Jamie, Saha, Chandan, Sanchez, Irene, deLavallade, Hugues, McLornan, Donal P, Harrison, Claire N
Format: Article
Language:English
Subjects:
Essential Thrombocythaemia
IFN
MPN
Polycythaemia Vera
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV). FDA approval for PV, regardless of treatment history, was subsequently granted in November 2021. We hereby demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at variable doses. It corroborates reports of efficacy of ropegIFN in patients with PV and use in pregnancy.
ISSN:2213-0489
2213-0489
DOI:10.1016/j.lrr.2022.100360